Recombinant PEN-2 is produced via heterologous expression systems optimized for structural and functional fidelity:
E. coli-expressed PEN-2 is most common due to high yield and cost-effectiveness, though mammalian systems enable native-like folding for functional assays .
Recombinant PEN-2 is pivotal in elucidating γ-secretase mechanisms and disease pathology:
APP Processing: PEN-2 modulates Aβ42/Aβ40 ratios, a therapeutic target in AD .
γ-Secretase Inhibitors: Recombinant PEN-2 aids in testing inhibitors like DAPT and BMS 299897 .
Pathway Activation: PEN-2-deficient cells show impaired Notch cleavage, linking γ-secretase dysfunction to developmental disorders .
Drug Development: Selective γ-secretase modulators (GSMs) spare Notch signaling, reducing off-target effects .
| Mutation | Region | Effect on PS1 Endoproteolysis | Effect on Activity |
|---|---|---|---|
| N33A | TMD1 (N-terminal) | ↓ (Reduced) | ↓ (↓ Activity) |
| I53A | Loop | ↓ (↓ Stability) | ↓ (↓ Activity) |
| D90A/F94A | C-Terminal | – (No effect) | ↓ (↓ Stability) |
Data synthesized from systematic mutagenesis studies .
PS1 Endoproteolysis: PEN-2 triggers PS1 cleavage, generating active N- and C-terminal fragments .
Complex Stabilization: The C-terminal domain prevents proteasomal degradation of PS fragments .
Alzheimer’s Therapeutics: PEN-2’s role in Aβ42/Aβ40 modulation positions it as a target for GSMs .
Cancer Research: γ-Secretase inhibitors (e.g., BMS 299897) target Notch signaling in oncogenesis .
Rare Diseases: PSENEN haploinsufficiency causes familial acne inversa (ACNINV2), linking γ-secretase to skin pathology .